MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot

Core Viewpoint - Moderna's shares increased by approximately 4% following the EMA's CHMP recommendation for marketing authorization of its mRNA-based combination vaccine, mCombriax, targeting COVID-19 and influenza [1][9]. Group 1: Regulatory Approval Process - The CHMP's recommendation will be reviewed by the European Commission, with a final decision anticipated soon [2]. - If approved, mCombriax will be Moderna's fourth marketed product in the EU, following two COVID-19 vaccines and an RSV vaccine [2]. Group 2: Clinical Study Results - The recommendation was supported by data from a pivotal phase III study that met its primary endpoints, showing that a single dose of mCombriax produced higher immune responses against COVID-19 and influenza compared to standalone vaccines [3][9]. - The study involved around 8,000 adults, split into two age cohorts: one for adults aged 65 and older and another for those aged 50 to 64, comparing mCombriax with existing influenza vaccines [4]. Group 3: Stock Performance - Year-to-date, Moderna's stock has surged approximately 82%, significantly outperforming the industry average growth of 10% [7]. Group 4: Product Details and Future Filings - mCombriax combines Moderna's mNexspike and mRNA-1010, an investigational influenza vaccine, with regulatory filings currently under review in multiple regions including the US, Europe, Canada, and Australia [8]. - A final decision by the FDA regarding mCombriax is expected by August 5, 2026 [8]. Group 5: FDA Review and Challenges - Moderna had previously submitted a regulatory filing for mCombriax to the FDA, which was voluntarily withdrawn in May 2025 due to requests for additional efficacy data for the flu component [10]. - The FDA initially refused to review the mRNA-1010 filing but later reversed its decision after Moderna proposed an age-based regulatory pathway for approval [11].